MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Treatment Plan for Managed Access Program (MAP) to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera (PV)

The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with Polycythemia Vera. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Study Overview

• Status: No longer available
• Conditions: Polycythemia Vera
• Intervention / Treatment: Drug: Ruxolitinib

Detailed Description

The requesting Treating Physician must submit a request for access to drug (often referred to as Compassionate Use) to Novartis which will review and approve by the medical team experienced with the drug and indication.

• Study Type: Expanded Access
• Expanded Access Type: Individual Patients

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Orange, New South Wales, Australia, 2800
      • Novartis Investigative Site
• Belgium
  • Leuven, Belgium, 3000
    • Novartis Investigative Site
• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2N 2T9
      • Novartis Investigative Site
• Iran
  • Tehran, Iran, 11367
    • Novartis Investigative Site
• Israel
  • Kfar Saba, Israel, 44281
    • Novartis Investigative Site
  • Rehovot, Israel, 7610001
    • Novartis Investigative Site
  • Tel Aviv, Israel, 6423906
    • Novartis Investigative Site
  • Tel Giborim Holon, Israel, 58100
    • Novartis Investigative Site
  • Israel
    • Kfar Saba, Israel, Israel, 44281
      • Novartis Investigative Site
• Netherlands
  • Groningen, Netherlands, 9700RB
    • Novartis Investigative Site
• Poland
  • Gdansk, Poland, 80-214
    • Novartis Investigative Site
  • Katowice, Poland, 40-027
    • Novartis Investigative Site
  • Krakow, Poland, 31-501
    • Novartis Investigative Site
  • Warsaw, Poland, 00-791
    • Novartis Investigative Site
  • Warsaw, Poland, 04-141
    • Novartis Investigative Site
  • Wałbrzych, Poland, 58-309
    • Novartis Investigative Site
  • Wroclaw, Poland, 50-367
    • Novartis Investigative Site
• United Kingdom
  • Hereford, United Kingdom, HR1 2ER
    • Novartis Investigative Site
  • Kent, United Kingdom, CT9 4AN
    • Novartis Investigative Site
  • London, United Kingdom, WC1E 6HX
    • Novartis Investigative Site
  • London, United Kingdom, NW3 2PF
    • Novartis Investigative Site
  • London, United Kingdom, SE5 8AD
    • Novartis Investigative Site
  • Oxford, United Kingdom, OX3 7LJ
    • Novartis Investigative Site
  • Poole, United Kingdom, BH15 2JB
    • Novartis Investigative Site
  • Salisbury, United Kingdom, SP2 8BJ
    • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 99 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Patients eligible for inclusion in this Treatment Plan have to meet all of the following criteria:

1. Male or female aged 12 or over
2. Confirmed diagnosis of PV based on World Health Organization (WHO) criteria
3. Patients must have a treatment history for PV that meets the definition of resistance or intolerance to hydroxyurea (HU) or other cytoreductive therapy
4. Patients with a peripheral blood blast count of 0% at screening
5. Patients must have recovered or stabilized sufficiently from adverse drug reactions associated with prior treatments before beginning treatment with ruxolitinib
6. Patients with an Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 Written patient informed consent must be obtained prior to start of treatment.

Exclusion Criteria:

Patients eligible for this Treatment Plan must not meet any of the following criteria:

1. History of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib.
2. Presence of an active uncontrolled infection including significant bacterial, fungal, viral (including CMV, EBV, HHV-6, HBV, HCV, BK or HIV) or parasitic infection requiring treatment. Infections are considered controlled if appropriate therapy has been instituted and, at the time of screening, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection. Patients with inactive chronic infection (without viral replication) can be enrolled.
3. History of progressive multifocal leuko-encephalopathy (PML).
4. Presence of severely impaired renal function defined by serum creatinine > 2 mg/dL (>176.8 μmol/L), or have estimated creatinine clearance < 30 ml/min measured or calculated by Cockroft Gault equation.

5. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are

   • women whose sexual orientation precludes intercourse with a male partner.
   • women whose partners have been sterilized by vasectomy or other means.
   • using a highly effective method of birth control (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some intrauterine devices (IUDs); periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable throughout the period of treatment and 30 days after treatment discontinuation.

   Any female aged 8 years and above is to be treated as a woman of child-bearing potential.

   Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL [for US only: and estradiol < 20 pg/mL] or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

6. Pregnancy
7. Not able to understand and to comply with treatment instructions and requirements

Study Plan

How is the study designed?

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start: December 7, 2022
• Primary Completion: December 7, 2022
• Study Completion: December 7, 2022

Study Registration Dates

• First Submitted: February 16, 2022
• First Submitted That Met QC Criteria: March 7, 2022
• First Posted (Actual): March 8, 2022

Study Record Updates

• Last Update Posted (Estimated): November 5, 2025
• Last Update Submitted That Met QC Criteria: October 31, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Keywords: Ruxolitinib; INC424; Jakavi; MAP; Manage access program
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Hematologic Diseases; Bone Marrow Diseases; Myeloproliferative Disorders; Bone Marrow Neoplasms; Hematologic Neoplasms; Hemic and Lymphatic Diseases; Polycythemia Vera; ruxolitinib
• Other Study ID Numbers: CINC424B2002I

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No